Genovate Biotechnology Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was TWD 528.51 million compared to TWD 438.76 million a year ago. Net income was TWD 29.33 million compared to net loss of TWD 12.32 million a year ago.

Basic earnings per share from continuing operations was TWD 0.27 compared to basic loss per share from continuing operations of TWD 0.11 a year ago. Diluted earnings per share from continuing operations was TWD 0.27 compared to diluted loss per share from continuing operations of TWD 0.11 a year ago.